新冠疫苗制造商诺瓦瓦克斯因销售额攀升而扭亏为盈

Core Viewpoint - Novavax reported a significant turnaround in its financial performance for Q4 2025, with a notable increase in revenue and a return to profitability [2][3]. Financial Performance - Q4 earnings per share were $0.11, compared to a loss of $0.51 per share in the same period last year, marking a successful turnaround [2]. - Q4 revenue reached $147 million, representing a 67% year-over-year increase [2]. - The company exceeded its cost reduction targets for R&D and SG&A expenses in 2025 and is tightening future spending goals, projecting R&D and SG&A expenses of $325 million in 2026, $225 million in 2027, and $200 million or less in 2028 [2]. Management Commentary - The CEO highlighted significant strategic progress in 2025, including achieving key milestones under the Sanofi agreement and advancing R&D efforts through collaborations [3]. - The company anticipates a strong start in 2026, particularly with the recent agreement with Pfizer, and is looking forward to more potential partnerships to drive innovation and value creation [3]. Revenue Guidance - Novavax provided revenue guidance for 2026, expecting adjusted total revenue between $230 million and $270 million, while market expectations are at $381.22 million [4]. - The company forecasts Nuvaxovid product sales of $35 million to $45 million and adjusted supply sales of $40 million to $50 million, reflecting ongoing collaborations with partners like the Serum Institute [4]. Technical Analysis - The stock is currently trading 8.4% above its 20-day simple moving average (SMA) and 9.2% above its 100-day SMA, indicating short-term strength [5]. - Over the past 12 months, the stock has shown a significant upward trend, nearing its 52-week high [5]. - The relative strength index (RSI) is at 44.45, indicating a neutral position, with no immediate bullish or bearish pressure evident from MACD signals [5][6]. Key Support and Resistance Levels - Key resistance level is at $12.00, while key support level is at $10.50 [7]. - Analyst consensus holds a "hold" rating with an average target price of $32.23, with recent analyst actions including a buy rating from BTIG and a downgrade from Morgan Stanley [7][8].